Abstract
Safety pharmacology is essential throughout the spectrum of drug discovery and development. Prior to first-in-human studies, safety pharmacology assays, tests, and models predict the clinical risk profile of a potential new drug. During clinical development, safety pharmacology can be used to explore—and potentially explain—both predicted and unpredicted side effects (e.g., adverse events, changes in vital signs, abnormal laboratory values) in order to refine the original clinical risk profile. This chapter will introduce the reader to safety pharmacology’s role in translational medicine: the science of translating potential drugs’ on- and off-target nonclinical properties to clinical consequences in order to select the best drug candidates to move into early clinical testing. Case studies will be used to illustrate the importance of safety pharmacology testing throughout all phases of drug development.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bass AS, Kinter LB, Williams P (2004) Origins, practises and future of safety pharmacology. J Pharmacol Toxicol Methods 49:145–151
Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 11:909–922
ICH Efficacy Guidelines E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-anti-arrhythmic drugs (2005). http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 19 Apr 2015
FDA Guidance on IND Content and format (1998), 21CFR312.23. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.23. Accessed 19 Apr 2015
FDA Guidance for industry and review staff target product profile—a strategic development process tool (2007). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080593.pdf. Accessed 26 Nov 2013
21CFR58 Good laboratory practice for nonclinical laboratory studies. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58. Accessed 19 Apr 2015
Fletcher AP (1978) Drug safety tests and subsequent clinical experience. J R Soc Med 71:693–696
Greaves P, Williams A, Eve M (2004) First dose of potential new medicine to humans: how animals help. Nat Rev Drug Discov 3:226–236
Grosveld FC (2009) Gamma-secretase inhibitors: notch so bad. Nat Med 15:20–21
Li Y, Bohm C, Dodd R, Chen F, Qamar S, Schmitt-Ulms G, Fraser PE, St George-Hyslop PH (2014) Structural biology of presenilin 1 complexes. Mol Neurodegener 9:59
Lindgren S, Bass AS, Briscoe R, Bruse K, Friedrichs GS, Kallman MJ, Markgraf C, Patmore L, Pugsley MK (2008) Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 58:99–109
Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264(21):2788–2790
OECD (1998) Series on principles of good laboratory practice (GLP) and compliance monitoring. http://www.oecd.org/document/4/0,3746,en_2649_34377_2346175_1_1_1_1,00.html. Accessed 19 Apr 2015
Pugsley MK, Authier S, Curtis MJ (2008) Principles of safety pharmacology. Br J Pharmacol 154:1382–1399
Ringel M, Tollman P, Hersch G, Schulze U (2013) Does size matter in R&D productivity? If not, what does? Nat Rev Drug Discov 12:901–902
ICH Safety Guidelines S7A: Safety pharmacology studies for human pharmaceuticals (2000), S7B: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by Human Pharmaceuticals (2005). Accessed 31 May 2012
Staal JFT, Langerak AW (2008) Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica 93:493–497
Stebbings, R, Poole, S, Thorpe, R (2009) Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20:673–677
Whitebread S, Hamon J, Bojanic D, Urban L (2005) In vitro safety pharmacology: an essential tool for successful drug development. Drug Discov Today 10(21):1421–1433
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Morimoto, B.H., Castelloe, E., Fox, A.W. (2015). Safety Pharmacology in Drug Discovery and Development. In: Pugsley, M., Curtis, M. (eds) Principles of Safety Pharmacology. Handbook of Experimental Pharmacology, vol 229. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46943-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-46943-9_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46942-2
Online ISBN: 978-3-662-46943-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)